Investors.curis.com

Investor S Curis. > Fimepinostat (formerly known as CUDC-907), an orally available, small molecule inhibitor of HDAC and PI3K enzymes being investigated...

Never miss Investors.curis.com updates: Start reading the news feed of Investor S Curis right away! Unfortunately, we cannot detect RSS feed on this website, but you may observe related news or Investors.curis.com popular pages instead. It is generally safe for browsing, so you may click any item to proceed to the site.

News, stories and media buzz related to Investor S Curis

Subscribe to related news

Trillium to Provide Update on CD47 Program at the 2016 American Association for Cancer Research Annual Meeting
via military-technologies

TORONTO, ONTARIO--(Marketwired - April 14, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be providing an update on its SIRPaFc...
Roche/Janus Therapeutics Research Partnership Goal A Convenient Oral Medication For Lupus; Other Autoimmune Disorders
via lupusliqueens

Janus Biotherapeutics (Janus), a Boston, Massachusetts based autoimmunity therapeutics company dedicated to development of novel, orally available compounds for treating autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis...
Hutchison China Meditech Limited: Sulfatinib Phase Ib/II Results Presented at ENETS
via marketportalegypt

HONG KONG, CHINA—(Marketwired – Mar 10, 2017) – Hutchison China Meditech Limited ( NASDAQ : HCM ) ( AIM : HCM ) Press Release Chi–Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of European Neuroendocrine...
Chi-Med 2016 Interim Results
via saudiindustrydaily

HONG KONG, CHINA—(Marketwired – Aug 2, 2016) – Hutchison China Meditech Limited ( NASDAQ : HCM ) Nasdaq: HCM Hutchison China MediTech Limited (“Chi–Med”) Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance...
CRT Pioneer Fund Licenses Oncology Drug Targeting DNA Damage Response Checkpoint Kinase 1 (Chk1) to ProNAi
via cancertechnology

ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage drug development company advancing targeted therapeutics for the treatment of patients with cancer, today announced that it has obtained an exclusive license from the CRT Pioneer Fund LP for...

Investors.curis.com popular pages

Investor Relations - Curis - Investor Relations

The Investor Relations website contains information about Curis, Inc. business for stockholders, potential investors, and financial analysts.
Events & Presentations - Curis, Inc.

Investor Relations In This Section...

Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology (NASDAQ:CRIS)

-- Latest analysis of data presented at the American Society of Hematology's annual meeting in December, 2015 ---- CUDC-907 demonstrated objective responses, including complete responses, in patients ...